Edition:
United States

Aralez Pharmaceuticals Inc (ARLZ.OQ)

ARLZ.OQ on NASDAQ Stock Exchange Global Select Market

1.48USD
8 Dec 2017
Change (% chg)

$0.08 (+5.71%)
Prev Close
$1.40
Open
$1.45
Day's High
$1.50
Day's Low
$1.39
Volume
53,227
Avg. Vol
119,893
52-wk High
$5.17
52-wk Low
$0.95

Latest Key Developments (Source: Significant Developments)

Aralez Announces Departure Of Chief Financial Officer
Thursday, 30 Nov 2017 05:00pm EST 

Nov 30 (Reuters) - Aralez Pharmaceuticals Inc ::ARALEZ ANNOUNCES DEPARTURE OF CHIEF FINANCIAL OFFICER.ARALEZ PHARMACEUTICALS INC - ‍SCOTT J. CHARLES, CHIEF FINANCIAL OFFICER, IS LEAVING COMPANY​.ARALEZ PHARMACEUTICALS INC - MICHAEL KASETA WILL ASSUME POSITION OF INTERIM CHIEF FINANCIAL OFFICER.ARALEZ PHARMACEUTICALS INC - ‍ PRIOR TO JOINING ARALEZ, KASETA SERVED AS CFO OF SANOFI NORTH AMERICA, GLOBAL SERVICES​.  Full Article

Lannett Announces Agreement For Authorized Generic Version Of Toprol-XL
Wednesday, 29 Nov 2017 04:47pm EST 

Nov 29 (Reuters) - Lannett Company Inc ::LANNETT ANNOUNCES AGREEMENT FOR AUTHORIZED GENERIC VERSION OF TOPROL-XL®.LANNETT COMPANY INC - FINANCIAL TERMS WERE NOT DISCLOSED..LANNETT COMPANY INC - HAS ENTERED INTO AN AGREEMENT WITH ARALEZ PHARMACEUTICALS TRADING DAC.LANNETT COMPANY - ‍AGREEMENT WITH ARALEZ PHARMACEUTICALS TRADING DAC TO BECOME EXCLUSIVE DISTRIBUTOR IN U.S. OF AUTHORIZED GENERIC VERSION OF TOPROL-XL​.LANNETT COMPANY INC - DEAL TO BECOME EXCLUSIVE DISTRIBUTOR IN U.S. OF TOPROL-XL EXTENDED RELEASE TABLETS IN 25 MG, 50 MG, 100 MG AND 200MG.  Full Article

Aralez Pharmaceuticals files for mixed shelf offering of up to $100 mln - SEC filing‍​
Thursday, 9 Nov 2017 05:30pm EST 

Nov 9 (Reuters) - Aralez Pharmaceuticals Inc :Aralez Pharmaceuticals Inc - files for mixed shelf offering of up to $100 million - SEC filing‍​.  Full Article

Aralez sees 2018 net revenues $140 mln to $160 mln‍​
Thursday, 9 Nov 2017 07:00am EST 

Nov 9 (Reuters) - Aralez Pharmaceuticals Inc :Aralez announces third quarter 2017 financial results and achieves profitability on an adjusted EBITDA basis for the first time in the third quarter.Aralez Pharmaceuticals Inc - ‍provides updated 2017 full-year guidance and preliminary 2018 full-year outlook​.Aralez Pharmaceuticals Inc - ‍plans to implement further financial improvements designed to streamline U.S. business​.Aralez Pharmaceuticals Inc - ‍net loss in Q3 of 2017 was $24.4 million, or $0.37 per diluted share​.Qtrly total revenues, net $24.3 million versus $13.6 mln‍​.Aralez Pharmaceuticals Inc - ‍updated 2017 net revenues to be in a range of $95 million to $105 million​.Aralez Pharmaceuticals Inc - sees 2018 net revenues $140 million to $160 million‍​.  Full Article

Aralez qtrly loss per share ‍$0.42​
Wednesday, 9 Aug 2017 07:00am EDT 

Aug 9 (Reuters) - Aralez Pharmaceuticals Inc ::Aralez reports second quarter 2017 financial results.Aralez Pharmaceuticals Inc - ‍total revenues for 3 months ended June 30, 2017 were $27.6 million compared to $12.6 million for three months ended June 30, 2016​.Qtrly loss per share ‍$0.42​.Aralez Pharmaceuticals Inc - ‍as of June 30, 2017 company had cash and cash equivalents of approximately $55.8 million​.Aralez Pharmaceuticals Inc - ‍company currently believes it has sufficient cash to fund operations for at least next 12 months​.  Full Article

Aralez Pharmaceuticals announces commercial launch of Zontivity
Wednesday, 7 Jun 2017 06:30am EDT 

June 7 (Reuters) - Aralez Pharmaceuticals Inc ::Aralez announces national U.S. commercial launch of Zontivity.Has also advanced its goal of ensuring patient access to Zontivity with an out-of-pocket cost competitive to other branded anti-platelet agents.Aralez Pharmaceuticals Inc says national commercial launch of Zontivity in U.S. will commence this week.  Full Article

Aralez Pharmaceuticals Q1 loss per share of $0.42
Tuesday, 9 May 2017 07:00am EDT 

May 9 (Reuters) - Aralez Pharmaceuticals Inc :Aralez reports first quarter 2017 financial results.Qtrly loss per share of $0.42 per share.Qtrly net total revenues $26 million versus $8.1 million.  Full Article

Aralez Pharma says co and U.S. Government entered into modification of contract
Tuesday, 11 Apr 2017 04:30pm EDT 

Aralez Pharmaceuticals Inc : Aralez Pharma - on April 6, aralez us and u.s. government entered into modification of contract under which government exercised first renewal option under deal .Aralez Pharmaceuticals Inc - U.S. Government extended term of agreement by one year to April 28, 2018 with modified pricing for duration thereof.  Full Article

Aralez reports reduction in U.S. sales force
Wednesday, 5 Apr 2017 06:30am EDT 

Aralez Pharmaceuticals Inc : Aralez announces reduction in U.S. Sales force and cost savings program . Aralez Pharmaceuticals Inc - 32 pct reduction in U.S. sales force . Aralez Pharmaceuticals Inc - reduction in sales force is expected to reduce current annual run rate of operating expenses by approximately $7.5 million . Aralez Pharmaceuticals Inc - sales force restructuring is expected to yield savings for 2017 and beyond . Aralez Pharmaceuticals Inc - strategic realignment of resources with an emphasis on zontivity launch . Aralez Pharmaceuticals says as a result of sales force reduction, anticipates it will incur cash severance costs of approximately $0.6 million in q2 of 2017 . Aralez Pharmaceuticals Inc - company intends to communicate details of the plan in its q1 2017 earnings release to be issued in early may 2017 . Aralez Pharma- plan includes realignment of certain financial resources to support phased launch of zontivity that is expected to begin in mid-april . Aralez Pharmaceuticals Inc says is in process of finalizing its overall cost savings plan . Aralez Pharmaceuticals Inc - cost savings plan includes significant decrease in marketing spend on yosprala .Aralez Pharma-has begun other initiatives expected to reduce spending across business, some of which were already assumed in previously issued financial guidance.  Full Article

Aralez CEO purchases 500,000 shares of company common stock on open market
Monday, 20 Mar 2017 06:30am EDT 

Aralez Pharmaceuticals Inc : Aralez Pharmaceuticals- Adrian Adams, CEO, acquired additional 500,000 shares of company's common stock on March 15, 2017 in open-market purchases . Aralez Pharmaceuticals - shares were purchased at an average price of $2.46 per share, for an aggregate purchase price of approximately $1.2 million .Adams now owns about 3.6 million shares of company's common stock.  Full Article

BRIEF-Aralez Pharmaceuticals files for mixed shelf offering of up to $100 mln - SEC filing‍​

* Aralez Pharmaceuticals Inc - files for mixed shelf offering of up to $100 million - SEC filing‍​ Source text: (http://bit.ly/2zrTHPn) Further company coverage: